T Cell Therapy
Adoptive T cell therapy has brought excitement to immuno-oncology research and hope to cancer patients who are out of treatment options. The most popular form of T cell for therapy are chimeric antigen receptor (CAR) T cells. These cells are engineered to express a synthetic transmembrane receptors containing the variable domain of an antibody to redirect their specificity to recognize and eliminate cancer cells upon infusion in patients.
Below is a collection of scientific resources for your T cell therapy research.
Rational Combination of Cancer Therapies with PD1 Axis Blockade
This free wallchart from Nature Reviews Cancer and Nature Reviews Immunology provides a detailed overview of cancer-immune pathways, combination immunotherapies, and more.
Get Your Free Copy >- Transform Intracellular Delivery Using the CellPore™ Transfection SystemIntracellular delivery of molecules is a key step in biological research, but traditional transfection methods are often limited in their ability to efficiently deliver macromolecules across diverse cell types without altering cell phenotype and function. <br><br>Watch this on-demand webinar—originally presented as a workshop at AAI 2025—to learn how the CellPore™ Transfection System addresses these limitations by using mechanoporation to create transient membrane pores, enabling direct cytosolic delivery with high efficiency and cell viability.
- T Cell Nomenclature: From Subsets to ModulesA modular framework for classifying T cells by lineage, function, migration, differentiation, and antigen context.
- "Therapeutic T Cell Engineering" Featuring Drs. Carl June and Philipp RommelOn this episode of the Immunology Podcast, Drs. Carl June and Philipp Rommel discuss their research in lymphocyte biology, with a major translational focus on ex vivo T cell engineering for cancer and HIV cell-based therapies.
- Production of Chimeric Antigen Receptor T CellsThis free Nature Protocols Wallchart summarizes the processes involved in producing CAR T cells for therapy.
- Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung CancerIn this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.<br><br>This webinar is part of the “Translational T Cell Talks: Scaling for the Future†event hosted in collaboration with Scientist.com on June 11, 2024. <a href="/translational-t-cell-talks-2024">View the rest of the talks and read the Q&A transcripts.</a>
